ArticleBiochemical genetics2026
The m6A Reader IGF2BP2 Suppresses Ferroptosis in Nasopharyngeal Carcinoma by Stabilizing NRF2 mRNA.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nuclear factor erythroid 2-related factor 2 (NRF2) is a central transcriptional regulator of the antioxidant response and a key inhibitor of ferroptosis, and its overexpression is frequently observed in various cancers. However, the mechanisms underlying its dysregulation in nasopharyngeal carcinoma (NPC) remain poorly understood. In this study, we combined bioinformatic analysis with functional experiments to investigate the post‑transcriptional regulation of NRF2 in NPC. Using weighted gene co-expression network analysis (WGCNA) based on the GSE68799 dataset and differential expression analysis of NPC transcriptomic data, we identified NRF2 as a candidate gene associated with NPC progression. Functional studies confirmed that NRF2 inhibits ferroptosis in NPC cells. Mechanistically, we demonstrated that the m6A reader protein insulin‑like growth factor 2 mRNA‑binding protein 2 (IGF2BP2) binds to and stabilizes NRF2 mRNA in an m6A‑dependent manner. Depletion of IGF2BP2 downregulated NRF2 expression and accelerated NRF2 mRNA decay. Notably, inhibition of methyltransferase activity by S-Adenosyl-L-homocysteine (SAH) reduced m6A modification on NRF2 mRNA and impaired its interaction with IGF2BP2. Furthermore, IGF2BP2 knockdown impaired the NRF2/HO-1/GPX4 axis, leading to a significant reduction in GPX4 enzymatic activity and promoted ferroptosis, effects that were rescued by the NRF2 activator dimethyl fumarate (DMF). Collectively, these results reveal that IGF2BP2 stabilizes NRF2 mRNA via m6A modification to suppress ferroptosis, thereby promoting NPC cell survival.
Indexed as
Identifiers
42496933What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.